Bio-Rad

10X Genomics' GemCode platform

Several early-access customers presented results from the 10X technology at the meeting.

Bio-Rad reported $598.2 million in revenues for the quarter, down from $602.6 million a year ago but surpassing the average analysts' estimate of $593.4 million.

The research may prove relevant to understanding human diversity as well as the genetic underpinning of certain CNV-related disorders.

An increasing number of publications using droplet-based digital PCR platforms suggests acceptance and uptake of the technology.

The company plans to launch a PCR-based test for measuring three genes in the plasma of lung cancer patients and is also at work on an NGS-based panel.

San Francisco

Officials from Exact Sciences, Cepheid, Bio-Rad, Biocartis, and NanoString provided strategic updates at the conference. 

Trends included expanding test menus and a possible tipping point for point-of-care.

Two new studies demonstrate improved methods using droplet digital PCR to detect very low viral loads in HIV-positive patients, pushing the detection threshold lower than that of real-time PCR.

NEW YORK (GenomeWeb) – Though reverse transcription of RNA to cDNA is an essential first step for a growing number of genomics applications, researchers have long known of problems associated with RT and its effects on study results.

NEW YORK (GenomeWeb) – Fitch Ratings today affirmed the ratings of Bio-Rad Laboratories, including the issuer default rating, at BBB- .

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.